Nemera

Nemera is a private, revenue-generating contract development and manufacturing organization (CDMO) specializing in drug delivery devices and combination products. Founded in 1999 and headquartered near Lyon, France, the company operates globally with a strong patient-centric vision and ambition to reach $1 billion in revenue by 2030. It offers a comprehensive portfolio of services and proprietary device platforms, with notable recent expansions in high-growth areas like GLP-1 injectables and preservative-free multi-dose eyedroppers. Nemera positions itself as a holistic partner, focusing on quality, innovation, and accelerating its clients' sprint to market.

Design, development, and manufacturing platform for a broad range of drug delivery devices including inhalation systems, nasal sprays, auto-injectors, pen injectors, safety devices, and multi-dose preservative-free eyedroppers (e.g., Novelia®). Offers end-to-end combination product services from strategy to commercialization.

Nemera competes in the fragmented but competitive drug delivery and combination product CDMO market. Key competitors include large, publicly traded players like West Pharmaceutical Services, Gerresheimer, and Schott AG, as well as other specialized private firms. Differentiation is achieved through a holistic service model, proprietary device platforms (e.g., Novelia®), and a strong patient-centric design philosophy.